Journal
NATURE REVIEWS CANCER
Volume 10, Issue 11, Pages 775-783Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrc2943
Keywords
-
Categories
Funding
- Ligue Nationale contre le Cancer, France
- Institut Universitaire de France, France
- Institut National du Cancer, France
- European Economic community, National High Tech Program for Biotechnology of China, the Chinese National Key Basic Research Project, China
- National Natural Science Foundation of China, the Key Discipline Program of Shanghai Municipal Education Commission, China
Ask authors/readers for more resources
The fusion oncogene, promyelocytic leukaemia (PML)-retinoic acid receptor-alpha (RARA), initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and increased self-renewal of leukaemic progenitor cells. The current standard of care is retinoic acid (RA) and chemotherapy, but arsenic trioxide also cures many patients with APL, and an RA plus arsenic trioxide combination cures most patients. This Review discusses the recent evidence that reveals surprising new insights into how RA and arsenic trioxide cure this leukaemia, by targeting PML-RAR alpha for degradation. Drug-triggered oncoprotein degradation may be a strategy that is applicable to many cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
